• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Exploring FNDC4 as a biomarker for prognosis and immunotherapy response in lung adenocarcinoma.

作者信息

Xu Shengshan, Lu Zhuming

机构信息

Department of Thoracic Surgery, Jiangmen Central Hospital, Jiangmen, Guangdong, China.

出版信息

Asian J Surg. 2024 Sep 13. doi: 10.1016/j.asjsur.2024.09.054.

DOI:10.1016/j.asjsur.2024.09.054
PMID:39277471
Abstract
摘要

相似文献

1
Exploring FNDC4 as a biomarker for prognosis and immunotherapy response in lung adenocarcinoma.探索纤连蛋白结构域包含蛋白4（FNDC4）作为肺腺癌预后和免疫治疗反应的生物标志物。
Asian J Surg. 2024 Sep 13. doi: 10.1016/j.asjsur.2024.09.054.
2
Overexpression of FNDC4 constrains ovarian cancer progression by promoting cell apoptosis and inhibiting cell growth.FNDC4的过表达通过促进细胞凋亡和抑制细胞生长来抑制卵巢癌进展。
J Cancer. 2023 Oct 16;14(18):3416-3428. doi: 10.7150/jca.88964. eCollection 2023.
3
Prognostic value of transcriptional expression of fibronectin type III domain-containing 4 (FNDC4) in head and neck carcinoma patients treated with chemoradiotherapy.FNDC4 转录表达对头颈癌患者放化疗预后的价值。
Clin Transl Oncol. 2022 Nov;24(11):2175-2180. doi: 10.1007/s12094-022-02870-3. Epub 2022 Jun 25.
4
Correlation of the prognostic value of FNDC4 in glioblastoma with macrophage polarization.胶质母细胞瘤中FNDC4的预后价值与巨噬细胞极化的相关性。
Cancer Cell Int. 2022 Sep 2;22(1):273. doi: 10.1186/s12935-022-02688-7.
5
FNDC4 acts as an extracellular factor to promote the invasiveness of hepatocellular carcinoma partly via the PI3K/Akt signalling pathway.FNDC4 作为一种细胞外因子，通过 PI3K/Akt 信号通路促进肝癌的侵袭性。
Cancer Med. 2021 Oct;10(20):7242-7252. doi: 10.1002/cam4.4225. Epub 2021 Aug 21.
6
Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.构建并验证 T 细胞增殖调节剂相关标志物用于预测肺腺癌患者的预后和免疫治疗反应。
Front Immunol. 2023 Apr 4;14:1171145. doi: 10.3389/fimmu.2023.1171145. eCollection 2023.
7
Fibronectin type III domain containing 4 alleviates myocardial ischemia/reperfusion injury via the Nrf2-dependent antioxidant pathway.纤维连接蛋白 III 型结构域包含 4 通过 Nrf2 依赖性抗氧化途径减轻心肌缺血/再灌注损伤。
Free Radic Biol Med. 2024 Nov 1;224:256-271. doi: 10.1016/j.freeradbiomed.2024.08.033. Epub 2024 Aug 26.
8
FNDC4 acts as an anti-inflammatory factor on macrophages and improves colitis in mice.FNDC4在巨噬细胞上作为一种抗炎因子发挥作用，并改善小鼠的结肠炎。
Nat Commun. 2016 Apr 12;7:11314. doi: 10.1038/ncomms11314.
9
Fibronectin Type III Domain Containing 4 attenuates hyperlipidemia-induced insulin resistance via suppression of inflammation and ER stress through HO-1 expression in adipocytes.纤连蛋白结构域蛋白 4 通过脂肪细胞中 HO-1 的表达抑制炎症和内质网应激来减轻高脂血症诱导的胰岛素抵抗。
Biochem Biophys Res Commun. 2018 Jul 7;502(1):129-136. doi: 10.1016/j.bbrc.2018.05.133. Epub 2018 May 24.
10
FNDC4 Inhibits RANKL-Induced Osteoclast Formation by Suppressing NF-B Activation and CXCL10 Expression.FNDC4 通过抑制 NF-B 激活和 CXCL10 表达抑制 RANKL 诱导的破骨细胞形成。
Biomed Res Int. 2018 May 30;2018:3936257. doi: 10.1155/2018/3936257. eCollection 2018.

引用本文的文献

1
Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer.苯美司他巴特、安罗替尼与化疗用于广泛期小细胞肺癌患者的成本效益评估
Front Pharmacol. 2025 Aug 19;16:1524108. doi: 10.3389/fphar.2025.1524108. eCollection 2025.
2
Development and validation of a nomogram for predicting immunotherapy outcomes in lung cancer patients using clinical and blood biomarkers.使用临床和血液生物标志物预测肺癌患者免疫治疗结果的列线图的开发与验证
BMC Cancer. 2025 Aug 22;25(1):1353. doi: 10.1186/s12885-025-14559-1.
3
Evaluating the efficacy of neoadjuvant immunotherapy combined with chemotherapy for stage IIIa non-small cell lung cancer.
评估新辅助免疫疗法联合化疗治疗Ⅲa期非小细胞肺癌的疗效。
Sci Rep. 2025 Jul 31;15(1):28003. doi: 10.1038/s41598-025-13917-0.
4
Machine learning developed an immune evasion signature for predicting prognosis and immunotherapy benefits in lung adenocarcinoma.机器学习开发了一种免疫逃逸特征，用于预测肺腺癌的预后和免疫治疗效果。
Front Cell Dev Biol. 2025 Jun 19;13:1622345. doi: 10.3389/fcell.2025.1622345. eCollection 2025.
5
Influence of migrasome-associated long noncoding RNAs on the immune microenvironment and prognosis in lung adenocarcinoma.迁移小体相关长链非编码RNA对肺腺癌免疫微环境及预后的影响
Discov Oncol. 2025 Jun 20;16(1):1168. doi: 10.1007/s12672-025-03000-5.
6
microRNA-196b-5p expression in cancer tissues is closely associated with clinical and pathological characteristics and prognosis of patients with non-small cell lung cancer.微小RNA-196b-5p在癌组织中的表达与非小细胞肺癌患者的临床病理特征及预后密切相关。
J Cardiothorac Surg. 2025 Jun 18;20(1):264. doi: 10.1186/s13019-025-03508-5.
7
LncRNA OIP5-AS1 suppresses lung adenocarcinoma progression and modulates macrophage polarization through the miR-429/DOCK4 regulatory axis.长链非编码RNA OIP5-AS1通过miR-429/DOCK4调控轴抑制肺腺癌进展并调节巨噬细胞极化。
Front Pharmacol. 2025 May 20;16:1569644. doi: 10.3389/fphar.2025.1569644. eCollection 2025.
8
Liposomes, immune cells, and lung cancer subtypes: A bidirectional Mendelian randomization study.脂质体、免疫细胞与肺癌亚型：一项双向孟德尔随机化研究
Medicine (Baltimore). 2025 Jun 13;104(24):e42795. doi: 10.1097/MD.0000000000042795.
9
Unraveling the role of HDAC3 as an immunotherapy prognostic biomarker and therapeutic target in advanced non-small cell lung cancer.揭示HDAC3作为晚期非小细胞肺癌免疫治疗预后生物标志物和治疗靶点的作用。
Respir Res. 2025 Jun 12;26(1):214. doi: 10.1186/s12931-025-03275-w.
10
GNG7 as a tumor-suppressor gene in lung adenocarcinoma: implications for prognosis and immune-based therapies.GNG7作为肺腺癌中的一种肿瘤抑制基因：对预后和免疫治疗的意义。
Front Oncol. 2025 May 27;15:1588646. doi: 10.3389/fonc.2025.1588646. eCollection 2025.